Read this news on the benefits we can get from onions as well. It may not be good for your breath but it's worth it if it can lower your cholesterol and fight tumors right? Read on:
Apples are worth eating every day, but I did mean onions. We were on a tangent during that talk, and onions happen to lower the risk for stomach cancer, improve breathing, fight bacteria and improve cholesterol. Onions (and garlic) are rich in several sulfur compounds which offer protection against tumor growth, specifically in the stomach and intestines. Folks, that's natural sulfur, which is completely different from sulfa-based drugs, which can spark allergies for some. Moreover, the sulfur compounds in this little pharmacological powerhouse might keep your blood nice and thin and halt the growth of dangerous pathogens including salmonella and E. coli. Peel it and purify yourself.
In Georgia, where Vidalia onions are cultivated, the mortality rate from stomach cancer is about half the average for the United States. Also, the Chinese rank among the largest population of onion lovers, and guess what? Their risk of getting stomach cancer is 40 percent lower than it is for people who shy away from the bulbous beauties.
Onions are extremely rich in fructo-oligosaccharides compounds that feed your friendly flora. Think bifidobacteria, a micro-organism thought to relieve inflammatory bowel conditions and boost immune function. In addition to breaking down certain cancer-causing compounds and reducing the body's absorption of cholesterol, these particular friendly bugs also fight fungus. For all you social types, onions provide relief from gas and flatulence. Obviously, they could give you dragon breath, so pick your stink.
Read more from this Tulsa World article at http://www.tulsaworld.com/scene/article.aspx?subjectid=361&articleid=20110115_222_D4_bDearP564332
Thursday, January 27, 2011
Sunday, January 23, 2011
Learn to get your cholesterol in check
Read this tip on checking your cholesterol. It's good to monitor it specially if you know you have it in your genes. Read on:
Food Network Kitchens
Q. High cholesterol runs in my family. What can I do to avoid it? A. High cholesterol can be caused by a combination of both genetics and having too many of the wrong substances in your diet. The three dietary culprits to be aware of and limit in your food are: Saturated fats Trans fats Dietary cholesterol Foods high in these substances can raise the LDL (low-density lipoprotein), the major cholesterol carrier in your blood. LDL cholesterol is also known as the "bad" cholesterol as a high amount in your blood can increase your risk of heart disease.
LDL cholesterol contributes to the buildup of cholesterol and other debris (also known as plaque) along the lining of the walls of arteries, causing them to narrow and reduce the flow of nutrient- and oxygen-rich blood to your heart, as well as other parts of your body.
If your heart is deprived of adequate amounts of blood, a heart attack can occur.
Even though saturated fats, trans fats and dietary cholesterol can raise your LDL cholesterol, saturated fats and trans fats are the bigger dietary threats.
Since diet can play such an important role in helping lower the "bad" LDL cholesterol, it is not surprising that many individuals have come to realize that they can fight heart disease with a knife and fork.
Wednesday, January 19, 2011
Tomatoes May Fight Cholesterol, Fat and Vascular Disease
Take a look at this interesting facts on tomotoes. Read on:
If you want to wage battle against cholesterol and other lipids (fat) that can contribute to vascular disease, then make tomatoes a big part of your diet. Scientists say this popular fruit contains a nutrient that can fight vascular disease such as stroke and arteriosclerosis.
Tomatoes fight more than cholesterol and fat
Excessive levels of lipids, such as cholesterol and triglycerides in the bloodstream, a condition known as dyslipidemia, can lead to potentially deadly diseases such as arteriosclerosis, cirrhosis, and stroke.
Scientists from Kyoto University and New Bio-industry Initiatives, Japan, report that a compound called 9-oxo-octadecadienoic extracted from tomatoes can boost oxidation of fatty acids and contribute to the regulation of lipid metabolism by the liver. These qualities indicate that 9-oxo-octadecadienoic acid can fight cholesterol and other lipids and therefore help prevent vascular diseases.
Vascular disease is a general term used to describe diseases that affect the blood vessels. The Vascular Disease Foundation offers information on nearly two dozen different conditions that fit this category, including abdominal aortic aneurysm, carotid artery disease, deep vein thrombosis, lymphedema, peripheral artery disease, and stroke.
Tomatoes are also valued for other health benefits. Much research has been dedicated to a potent antioxidant in tomatoes, lycopene, and its potential in the fight against various types of cancer, and especially prostate cancer. Tomatoes also contain excellent levels of other nutrients, including niacin, which helps lower cholesterol; and potassium, which reduces blood pressure and the risk of heart disease.
Dr. Teruo Kawada, who is from Kyoto University and who led the study, noted that “Finding a compound which helps the prevention of obesity-related chronic diseases in foodstuffs is a great advantage to tackling these diseases. It means that the tomato allows people to easily manage the onset of dyslipidemia through their daily diet.” To help the fight against cholesterol and other fats that contribute to vascular disease, enjoy more tomatoes.
more from here: http://www.emaxhealth.com/1275/tomatoes-may-fight-cholesterol-fat-and-vascular-disease
If you want to wage battle against cholesterol and other lipids (fat) that can contribute to vascular disease, then make tomatoes a big part of your diet. Scientists say this popular fruit contains a nutrient that can fight vascular disease such as stroke and arteriosclerosis.
Tomatoes fight more than cholesterol and fat
Excessive levels of lipids, such as cholesterol and triglycerides in the bloodstream, a condition known as dyslipidemia, can lead to potentially deadly diseases such as arteriosclerosis, cirrhosis, and stroke.
Scientists from Kyoto University and New Bio-industry Initiatives, Japan, report that a compound called 9-oxo-octadecadienoic extracted from tomatoes can boost oxidation of fatty acids and contribute to the regulation of lipid metabolism by the liver. These qualities indicate that 9-oxo-octadecadienoic acid can fight cholesterol and other lipids and therefore help prevent vascular diseases.
Vascular disease is a general term used to describe diseases that affect the blood vessels. The Vascular Disease Foundation offers information on nearly two dozen different conditions that fit this category, including abdominal aortic aneurysm, carotid artery disease, deep vein thrombosis, lymphedema, peripheral artery disease, and stroke.
Tomatoes are also valued for other health benefits. Much research has been dedicated to a potent antioxidant in tomatoes, lycopene, and its potential in the fight against various types of cancer, and especially prostate cancer. Tomatoes also contain excellent levels of other nutrients, including niacin, which helps lower cholesterol; and potassium, which reduces blood pressure and the risk of heart disease.
Dr. Teruo Kawada, who is from Kyoto University and who led the study, noted that “Finding a compound which helps the prevention of obesity-related chronic diseases in foodstuffs is a great advantage to tackling these diseases. It means that the tomato allows people to easily manage the onset of dyslipidemia through their daily diet.” To help the fight against cholesterol and other fats that contribute to vascular disease, enjoy more tomatoes.
more from here: http://www.emaxhealth.com/1275/tomatoes-may-fight-cholesterol-fat-and-vascular-disease
Saturday, January 15, 2011
Roger Newton's Esperion Therapeutics enters next phase of drug development
Take a look at this news on a new drug for lowering cholesterol. Read on:
Biotech firm Esperion Therapeutics has entered the second phase of the government's required three-stage regulatory process to test the effectiveness of its top drug candidate, the company announced today.
The firm, led by Ann Arbor entrepreneur Roger Newton, the scientist who co-discovered "bad" cholesterol-lowering drug Lipitor, said it had started its Phase 2 clinical study for a drug currently known as ETC-1002. The drug aims to help the body fight triglycerides and LDL cholesterol.
The Phase 2 study follows a Phase 1 study that was launched in fall 2009. Esperion said the Phase 1 study showed promising results, including the ability to lower LDL cholesterol and early indications that the drug is safe to consume.
Esperion said a second Phase 2 study will be launched later this year to study the drug's other possible benefits, which the company believes could include the ability to raise "good" HDL cholesterol and regulate glucose.
The current Phase 2 study will last 12 weeks and involves 176 patients with a history of hypercholesterolemia, a condition in which patients have consistently high cholesterol.
The development of this drug is separate from Esperion's ongoing work with the Cleveland Clinic, a partnership through which researchers are developing a therapy that would lower HDL cholesterol.
The market for the therapies Esperion is developing is lucrative.
"Cardio-metabolic diseases remain the leading cause of morbidity and mortality among men and women in industrialized countries worldwide," Newton said in a statement.
Esperion operates out of the 57,000-square-foot Michigan Life Science Innovation Center in Plymouth Township, a business incubator operated by economic development group Ann Arbor SPARK.
Newton first co-founded Esperion in the late 1990s and sold it in 2004 to Pfizer for $1.3 billion. Pfizer closed its Esperion division in 2007, but Newton raised venture capital funding and licensed technology from Pfizer to restart the company in 2008.
more from here http://www.annarbor.com/business-review/roger-newtons-esperion-therapeutics-enters-next-phase-of-drug-development/
Biotech firm Esperion Therapeutics has entered the second phase of the government's required three-stage regulatory process to test the effectiveness of its top drug candidate, the company announced today.
The firm, led by Ann Arbor entrepreneur Roger Newton, the scientist who co-discovered "bad" cholesterol-lowering drug Lipitor, said it had started its Phase 2 clinical study for a drug currently known as ETC-1002. The drug aims to help the body fight triglycerides and LDL cholesterol.
The Phase 2 study follows a Phase 1 study that was launched in fall 2009. Esperion said the Phase 1 study showed promising results, including the ability to lower LDL cholesterol and early indications that the drug is safe to consume.
Esperion said a second Phase 2 study will be launched later this year to study the drug's other possible benefits, which the company believes could include the ability to raise "good" HDL cholesterol and regulate glucose.
The current Phase 2 study will last 12 weeks and involves 176 patients with a history of hypercholesterolemia, a condition in which patients have consistently high cholesterol.
The development of this drug is separate from Esperion's ongoing work with the Cleveland Clinic, a partnership through which researchers are developing a therapy that would lower HDL cholesterol.
The market for the therapies Esperion is developing is lucrative.
"Cardio-metabolic diseases remain the leading cause of morbidity and mortality among men and women in industrialized countries worldwide," Newton said in a statement.
Esperion operates out of the 57,000-square-foot Michigan Life Science Innovation Center in Plymouth Township, a business incubator operated by economic development group Ann Arbor SPARK.
Newton first co-founded Esperion in the late 1990s and sold it in 2004 to Pfizer for $1.3 billion. Pfizer closed its Esperion division in 2007, but Newton raised venture capital funding and licensed technology from Pfizer to restart the company in 2008.
more from here http://www.annarbor.com/business-review/roger-newtons-esperion-therapeutics-enters-next-phase-of-drug-development/
Subscribe to:
Posts (Atom)